ADVANCED MEDICAL TECHNOLOGY ASSN lobbying for ADVANCED MEDICAL TECHNOLOGY ASSN

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$1,042,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 13

Centers For Disease Control & Prevention (CDC)
Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
Environmental Protection Agency (EPA)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Natl Security Council (NSC)
Office of Management & Budget (OMB)
SENATE
State, Dept of (DOS)
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 7

HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
S 1000
Saving Access to Laboratory Services Act
HR 2377
Saving Access to Laboratory Services Act
HR 2369
VALID Act of 2023
HR 3723
Medical Device Electronic Labeling Act
HR 5662
Medical Device Recall Improvement Act
HR 3795
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used …

Lobbying activity 6

Medicare/Medicaid

Issues related to coverage of telehealth services Issues related to Medicare coverage for digital health technologies Issues related to physician fee schedule Issues related to H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act Issues related to S. 1000/H.R. 2377 Saving Access to Laboratory Services Act Issues related to Medicare coverage of FDA's breakthrough devices

Health Issues

Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology Issues related to FDAs third party review program

Budget/Appropriations

Issues related to appropriations and user fee funding for the Food and Drug Administration Issues related to appropriations for AI reimbursement and focused ultrasound

Taxation/Internal Revenue Code

Issues related to R&D Expense Amortization

Trade (domestic/foreign)

Tariffs on medical devices United States-Mexico-Canada Agreement (USMCA) Global Trade and EU Tariffs Export Controls on Biotech lab equipment US Brazil ATEC Protocol

Small Business

Issues related to the reauthorization of the Small Business Innovation Research (SBIR) program.